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Background: Evaluating chlamydia prevalence trends from sentinel sur-
veillance is important for understanding population disease burden over
time. However, prevalence trend estimates from surveillance data may be
misleading if they do not account for changes in risk profiles of individuals
who are screened (case mix) and changing performance of the screening
tests used.
Methods:We analyzed chlamydia screening data from a sentinel surveil-
lance population of 389,555 young women (1990–2012) and 303,699
young men (2003–2012) entering the US National Job Training Program.
This period follows the introduction of national chlamydia screening pro-
grams designed to prevent transmission and reduce population disease
burden. After ruling out bias due to case mix, we used an expectation-
maximization–based maximum likelihood approach to account for mea-
surement error from changing screening tests, and generated minimally
biased long-term chlamydia prevalence trend estimates among youth
and young adults in this sentinel surveillance population.
Results: Adjusted chlamydia prevalence among women was high
throughout the study period, but fell from 20% in 1990 to 12% in 2003,
and remained between 12% and 14% through 2012. Adjusted prevalence
among men was steady throughout the study period at approximately 7%.
For both women and men, adjusted prevalence was highest among Black
and American Indian youth and young adults, and in the Southern andMid-
western regions of the United States throughout the study period.
Conclusions: Our minimally biased trend estimates provide support for
an initial decrease in chlamydia prevalence amongwomen soon after the in-
troduction of national chlamydia screening programs. Constant chlamydia
prevalence in more recent years suggests that screening may not be suffi-
cient to further reduce chlamydia prevalence among high-risk youth and
young adults.
Chlamydia trachomatis (chlamydia) infection is usually asymp-tomatic, but can result in serious reproductive sequelae if left
untreated. In response to the high burden of chlamydia among
young women, the Centers for Disease Control and Prevention
introduced a federally funded chlamydia screening program in
the Northwestern region of the US in 1988. By 1995, screening
programs were implemented in all regions of the United States
as part of the Infertility Prevention Project.1,2 The screening pro-
grams strengthened clinical, educational, laboratory, and surveil-
lance operations related to chlamydia and supported screening
and treatment services for low-income, sexually active women at-
tending public clinics. The goals were to identify and treat infec-
tions, which in turn prevents transmission and reduces incidence
and prevalence.3
At the population level, a reduction in chlamydia preva-
lence should be observable in sentinel populations if national
screening programs have widespread impact.4 A primary source
for sentinel surveillance of chlamydia in the United States is the
National Job Training Program (NJTP), a vocational training pro-
gram for socioeconomically disadvantaged adolescents and young
adults administered by the Department of Labor.5–7 The NJTP
has maintained consistent eligibility criteria over time and screens
all entrants for chlamydia, making it a stable, high-risk population
ideal for monitoring chlamydia prevalence. AmongNJTPenrollees,
chlamydia prevalence trends spanning short periods (2–7 years)
between 1990 and 2008 have shown modest decreases,8–11 but
trend estimates over longer periods have not been reported.
Observed prevalence trends from sentinel surveillance
should be interpreted cautiously because of potential biases. Two
important sources of bias that can affect prevalence trend esti-
mates are time-varying measurement error from changing screen-
ing tests and sentinel population risk profiles. Changes in
measurement error can bias prevalence trend estimates when
new screening technologies with different sensitivities and speci-
ficities are used.3,12 Changes in population risk profiles, which
we refer to as “case mix,” can bias prevalence trend estimates
when the relative proportions of high- and low-risk individuals
screened in a sentinel population fluctuate.3 These biases may
mask changes in prevalence over time, and trend estimates that
do not properly account for changes in measurement error and
case mix may be misleading.
We examined chlamydia prevalence trends over 23 years
among female NJTP enrollees and over 10 years among male
NJTP enrollees, accounting for potential biases associated with
changing screening tests and case mix, to provide minimally biased
estimates within a high-risk population over an extended period.
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MATERIALS AND METHODS
Study Population
We analyzed annual cross-sectional chlamydia screening
data from NJTP enrollees from 1990 through 2012. US residents
age 16 through 24 years who meet low-income criteria and face
barriers to employment can enroll in the NJTP. Universal chla-
mydia screening of NJTP entrants began in 1990 for women and
2003 for men. Screening was performed by a national contract lab-
oratory that used several tests. From 1990 through 1997, cervical
swabs were tested by Pathfinder Enzyme Immunoassays (EIA)
(Sanofi Diagnostics Pasteur, Inc, Redmond, WA). From 1998
through 2006, screening was done with Gen-Probe PACE 2 DNA
hybridization probe (Gen-Probe Inc., San Diego, CA) of cervical
swabs or urine (men only), or beginning in March 2000, BD
ProbeTec ET strand displacement assay (SDA) (Becton-Dickinson,
Sparks, MD) of urine (women and men). After 2006, screening
was done by BD ProbeTec ETof vaginal or cervical swabs or urine
(women and men).
Eligible participants for these analyses were women and
men entering the NJTP who had a recorded chlamydia screen-
ing test result. Enrollees were excluded if their chlamydia test
result, race/ethnicity, region of residence, or screening test type
was unknown.
Screening Test Sensitivity and Specificity
Pairs of sensitivity and specificity estimates for each
screening test and sample type were generated through targeted
meta-analyses of existing literature. We searched PubMed and
Scopus using medical subject heading terms and keywords related
to chlamydia screening and diagnostic accuracy (Appendix 1,
http://links.lww.com/OLQ/A236). We included studies conducted
in North America or Europe that reported the diagnostic accuracy
of the Pathfinder EIA, Gen-Probe PACE 2, and BD ProbeTec ET,
and from which counts of true positive, true negative, false posi-
tive, and false negative tests could be extracted or calculated. Bi-
variate generalized linear mixed effects models with a logit link
were used to generate summary sensitivity and specificity esti-
mates and corresponding 95% confidence intervals (CI) (Table 1).
Case Mix
Chlamydia prevalence and case rates are associated with
race/ethnicity and geography, with Black youth and youth in the
South having the highest burden.5,13,14 To assess potential bias
from longitudinal changes in the demographics of NJTP enrollees,
we examined the racial/ethnic and geographical distributions of
enrollees over time. We visually inspected the distributions of
race/ethnicity and enrollment region using stacked bar charts,
and observed a uniform distribution over time for both factors
(Figures S2, http://links.lww.com/OLQ/A238 and S3, http://
links.lww.com/OLQ/A239). We also examined temporal trends
in enrollment by these factors using logistic regression, with
race/ethnicity or region as the dependent variable, and study year
(continuous) as the independent variable. No meaningful variation
in the relative proportion of race/ethnicity and region over time
was observed (results not shown). As these analyses suggested that
no meaningful case mix variation occurred, we excluded this po-
tential bias from further consideration in calculating adjusted chla-
mydia prevalence trend estimates.
Prevalence Trends
Wemodeled chlamydia prevalence trends using an expecta-
tion-maximization (EM)–based maximum-likelihood approach
that accounts for measurement error due to imperfect screening
test sensitivity and specificity.15 This approach uses EM to esti-
mate a maximum-likelihood logit regression model when the out-
come is measured with uncertainty, and allows the sensitivity and
specificity of screening tests to vary across observations. Our
models accounted for sensitivity and specificity estimates gener-
ated from our meta-analyses. Chlamydial infection (positive or
negative) was the dependent variable in all models and study year
(continuous) was the independent variable. The functional form of
year was assessed using Akaike Information Criteria and visual in-
spection, and included quadratic spline terms with three knots in
models for women and a quadratic term inmodels for men. Param-
eter estimates from maximum-likelihood regression models were
used to calculate the predicted probability (prevalence) of chla-
mydia across study years. Ninety-five percent CIs were obtained
by bootstrapping (n = 200). We compared trends from the EM
maximum-likelihood regression model (adjusted trends that ac-
count for time-varying measurement error) to trends from a logis-
tic regression model (unadjusted trends that do not account for
time-varying measurement error) to assess the impact of changing
screening tests on prevalence trend estimates. We also stratified by
race/ethnicity and region to examine subgroup differences.
Sensitivity Analyses
We conducted sensitivity analyses to account for random
and systematic error in the estimates of test sensitivity and speci-
ficity that were used to model prevalence. To account for random
error, we modeled prevalence using the upper and lower bounds of
the 95% CI around our summary sensitivity and specificity esti-
mates. To account for systematic error, we re-estimated GenProbe
TABLE 1. Summary Sensitivity and Specificity Estimates of Chlamydia Screening Tests
Screening Test (Sample Type) No. Studies(Ref ) Sensitivity (95% CI) Specificity (95% CI)
Women
Pathfinder EIA (Swab)* 2(1s, 2s) 72.92 (39.07–91.88) 99.64 (98.14–99.93)
Gen-Probe PACE 2 DNA Probe (Swab)† 11(1s,3s-12s) 80.07 (76.66–83.08) 99.21 (98.43–99.60)
BD ProbeTec ET SDA (Urine)‡ 4(14s,16s-18s) 87.82 (83.74–90.99) 99.10 (97.66–99.66)
BD ProbeTec ET SDA (Swab)§ 6(13s-18s) 87.49 (81.27–91.86) 99.47 (98.69–99.79)
Men
Gen-Probe PACE 2 DNA Probe (Urine)† 3(5s,9s,19s) 72.09 (60.07–81.61) 99.17 (97.04–99.77)
BD ProbeTec ET SDA (Urine)‡ 3(14s,16s,17s) 94.04 (91.54–95.83) 98.21 (91.32–99.65)
*Used for screening from 1990 through 1997.
†Used for screening from 1998 through 2006 for women, and 2003 through 2006 for men.
‡Used for screening from 2000 through 2012 for women, and 2003 through 2012 for men.
§Used for screening from 2007 through 2012.
PACE 2 and BD ProbeTec ET sensitivity and specificity using
more selective inclusion/exclusion criteria for the meta-analyses.
We excluded studies that used the test of interest in their reference
test definition (reference test bias) or performed repeat testing. We
used these new estimates to model adjusted prevalence.We did not
reestimate sensitivity and specificity of the Pathfinder EIA due to
the small number of studies in the initial meta-analysis.
Analyses were performed in Stata version 14.1 (College
Station, TX, 2015).
RESULTS
Screening Test Sensitivity and Specificity
Sensitivity increased over the study period. The estimated
sensitivity of EIA, DNA probe, and SDA for women was 73%,
80%, and 87%, respectively (Table 1). Among men, sensitivity
of DNA probe and SDAwas 72% and 94%, respectively. All tests
had specificities greater than 98%.
Chlamydia Prevalence Among Women
From 1990 through 2012, 439,992 women were screened
for chlamydia. Relatively few women had an uninterpretable
screening test result (n = 3466, 0.8%), or missing race/ethnicity
(n = 26,905, 6.1%) or region (n = 17,097, 3.9%). Chlamydia
screening test type was unknown for a small number of women
throughout the study period (n = 2969, 0.7%), and these data were
considered missing. After excluding women with uninterpretable
test results or missing data, 389,555 women (89% of women
screened for chlamydia) were included in analyses.
Most women were Black (58%) and approximately half
lived in the South (45%) (Table 2). Two thirdswere age 16 through
19 (69%), and few reported symptoms (3%). Approximately 36%
of women were tested for chlamydia via EIA, 24% were tested by
DNA probe, and the remainder was tested via SDA of swabs
(12%) or urine (28%).
Unadjusted chlamydia prevalence was high overall, ranging
between 15% and 10%. Unadjusted prevalence declined modestly
from1990 through 2003, before rising slightly through 2009 (Fig. 1).
After accounting for measurement error associated with
different screening tests, we observed a higher prevalence of chla-
mydia across all years and a sharper decline in adjusted prevalence
in the first half of the study, relative to unadjusted estimates (Fig. 1).
Adjusted prevalence was highest in 1990 at approximately 20%,
and steadily decreased to 12% by 2003. From 2004 through
2012, adjusted prevalence was relatively steady and rose to 14%
before dropping to 12%.
Black women had the highest prevalence of chlamydia
throughout the study, followed by American Indian, Hispanic,
and White women (Fig. 2). For all race/ethnicities, adjusted prev-
alence declined early on, with the sharpest decline occurring
among American Indian women (24% to 12%) and Black women
(23% to 14%). Among Hispanic andWhite women, adjusted prev-
alence declined from approximately 15% to 10% and 13% to 7%
respectively. Adjusting for time-varying measurement error re-
vealed a larger decline in prevalence for all race/ethnicities early
in the study, relative to unadjusted trends (Figure S4, http://links.
lww.com/OLQ/A240). In the second half of the study, adjusted
chlamydia prevalence remained relatively steady among White
and Hispanic women. Adjusted prevalence in Black women rose
modestly from 14% to 17% between 2003 and 2008, before begin-
ning to drop. American Indian women experienced an increase in
adjusted prevalence from 2008 through 2012 (12% to 16%).
Chlamydia prevalence was highest throughout the study
among women in the South, followed by the Midwest, Northeast,
and West. In all regions, adjusted prevalence was high in 1990,
ranging between 16% among women in the West to 21% among
women in the South (Figs. 3 and S5, http://links.lww.com/OLQ/
A241). Adjusted prevalence among women declined in the first
half of the study in all regions, and leveled out in the second half
among women in the West and Northeast. Modest increases in ad-
justed prevalence occurred among women in the South and Mid-
west between 2004 and 2009.
In sensitivity analyses, neither the magnitude nor shape of
the overall prevalence trend was substantially altered by using
the lower and upper bounds of the 95% CI around test sensitiv-
ity and specificity estimates (Figure S6, http://links.lww.com/
OLQ/A242). Reestimated test sensitivity and specificity values
were very similar to initial estimates, and modeling trends with
reestimated values also had minimal influence on the overall trend
(results not shown).
Chlamydia Prevalence Among Men
From 2003 through 2012, 370,047 men were screened for
chlamydia. Few men had an uninterpretable test result (n = 1288,
0.3%), or were missing race/ethnicity (n = 21,976, 5.9%). Region
and chlamydia screening test type were missing for 7486 (2.0%)
men and 35,598 (9.6%) men respectively. Overall, 303,699 men
(82% of men screened for chlamydia) were included in analyses.
Half of the men were Black (51%) and lived in the South
(49%) (Table 2). Two thirds (67%)were aged 16 through 19 years.
Few men reported symptoms (1%). Almost all men were
screened with SDA (99%). Unadjusted chlamydia prevalence re-
mained stable throughout the study, and fluctuated between 8%
and 9% (Fig. 1).
After accounting for measurement error, the adjusted prev-
alence of chlamydia among men decreased slightly in all years
relative to unadjusted estimates but remained steady over time at
approximately 7% (Fig. 1). Black men had the highest adjusted
prevalence across all years (approximately 11%), followed by
American Indian (approximately 5%), Hispanic (approximately
4%), and White men (approximately 1%) (Figs. 2 and S7, http://
links.lww.com/OLQ/A243). Adjusted prevalence was consis-
tently highest among men in the South, followed by the Midwest,
Northeast, and West (Fig. 3 and S8, http://links.lww.com/OLQ/
A244). Adjusted prevalence estimates generated from the upper
and lower bounds of the 95% CI around test sensitivity and spec-
ificity did not substantially alter trends (Figure S9, http://links.
lww.com/OLQ/A245).
DISCUSSION
Sentinel surveillance of chlamydia among NJTP enrollees
provides a unique opportunity to assess chlamydia prevalence
trends in high-risk youth and young adults and gain insights into
the possible impact of the national chlamydia screening pro-
gram. After ruling out bias due to case mix and adjusting for
time-varying measurement error associated with changing
screening tests, chlamydia prevalence among women declined
from 20% to 12% during the first 14 years of the study, and re-
mained between 12% and 14% through 2012. Adjusted chla-
mydia prevalence among men was stable from 2003 through
2012 (approximately 7%). For women and men, adjusted preva-
lence was highest among Black and American Indian youth and
young adults, and youth and young adults in the South and
Midwest throughout the study. Despite longstanding national
screening and treatment programs,5 chlamydia remains highly
prevalent among youth and young adults entering the NJTP.
The decline in chlamydia prevalence among women enter-
ing the NJTP during the 1990s coincided with scale-up of the
national screening program, possibly providing indirect support
for the early success of screening programs in reducing chlamydia
prevalence, specifically among high-risk young women.16 The de-
cline in prevalence stopped in 2003, raising the possibility that on-
going screening efforts for high-risk youngwomen are insufficient
to reduce prevalence further.
Adjusted chlamydia prevalence among men was steady
throughout the study. Screening for men started in 2003, when the
prevalence amongwomen began to stabilize. The flat trend suggests
that ongoing prevention efforts have been ineffective at reducing
chlamydia among men since 2003. This trend is perhaps unsurpris-
ing, as screening programs have primarily targeted women.
We observed large disparities in chlamydia prevalence by
race/ethnicity and region, with black and American Indian youth
and young adults, and youth and young adults in the South having
consistently higher prevalence compared to other races/ethnicities
and regions. Prevalence in these groups also increased modestly
during the latter half of the study. The overall trends among
women appear to be driven by prevalence trends among black
women and women residing in the South and Midwest, based on
TABLE 2. Characteristics of National Job Training Program Enrollees and Unadjusted Chlamydia Prevalence, 1990–2012
Women (n = 389,555) Men (n = 303,699)
Unadjusted Unadjusted
Characteristic No. Tested (Col %) No. Positive Prevalence (%)*† No. Tested (Col %) No. Positive Prevalence (%)*
Age, y
16–19 270,483 (69.4) 36,075 13.3 204,778 (67.4) 16,147 7.9
20–24 119,072 (30.6) 10,709 9.0 98,921 (32.6) 8567 8.7
Race/ethnicity
Black 224,936 (57.8) 32,424 14.4 155,045 (51.1) 19,031 12.3
White 91,173 (23.4) 6737 7.4 95,994 (31.6) 2761 2.9
Hispanic 61,449 (15.8) 6186 10.1 44,822 (14.8) 2713 6.1
American Indian 11,997 (3.1) 1437 12.0 7838 (2.6) 507 6.5
Region
Midwest 71,291 (18.3) 8672 12.2 51,361 (16.9) 4423 8.6
Northeast 67,385 (17.3) 7007 10.4 45,730 (15.1) 2893 6.3
South 174,056 (44.7) 24,288 14.0 149,464 (49.2) 14,983 10.0
West 76,823 (19.7) 6817 8.9 57,144 (18.8) 2415 4.2
Symptoms at Entrance
Yes 12,270 (3.2) 1834 15.0 3707 (1.2) 673 18.2
No 377,285 (96.9) 44,950 11.9 299,992 (98.8) 24,041 8.0
Test (sample type)
EIA (swab) 141,932 (36.4) 17,811 12.6 — — — —
DNA Probe (swab) 92,145 (23.7) 9463 10.3 — — — —
DNA Probe (urine) — — — — 954 (0.3) 83 8.7
SDA (swab) 47,690 (12.2) 6779 14.2 — — — —
SDA (urine) 107,788 (27.7) 12,731 11.8 302,745 (99.7) 24,631 8.1
Year of Test
1990 10,143 (2.6) 1518 15.0 — — — —
1991 18,086 (4.6) 2588 14.3 — — — —
1992 18,922 (4.9) 2380 12.6 — — — —
1993 20,132 (5.2) 2484 12.3 — — — —
1994 19,994 (5.1) 2722 13.6 — — — —
1995 18,151 (4.7) 2276 12.5 — — — —
1996 21,115 (5.4) 2235 10.6 — — — —
1997 15,389 (4.0) 1608 10.4 — — — —
1998 12,106 (3.1) 1424 11.8 — — — —
1999 12,709 (3.3) 1459 11.5 — — — —
2000 10,189 (2.6) 1138 11.2 — — — —
2001 5892 (1.5) 653 11.1 — — — —
2002 6443 (1.7) 674 10.5 — — — —
2003 16,095 (4.1) 1598 9.9 16,206 (5.3) 1447 8.9
2004 17,936 (4.6) 1862 10.4 32,593 (10.7) 2766 8.5
2005 19,114 (4.9) 1758 9.2 33,637 (11.1) 2849 8.5
2006 19,339 (5.0) 2611 13.5 32,652 (10.8) 2699 8.3
2007 20,825 (5.3) 2811 13.5 33,147 (10.9) 2683 8.1
2008 21,494 (5.5) 2743 12.8 33,158 (10.9) 2624 7.9
2009 21,288 (5.5) 2518 11.8 31,435 (10.4) 2411 7.7
2010 21,948 (5.6) 2669 12.2 30,421 (10.0) 2346 7.7
2011 22,162 (5.7) 2646 11.9 31,661 (10.4) 2581 8.2
2012 20,083 (5.2) 2409 12.0 28,789 (9.5) 2308 8.0
*Unadjusted prevalence was calculated as the total number of positive tests divided by the total number tested. Estimates differ slightly from estimates
derived from logistic regression models.
†A total of 9038 and 9717womenwere tested for chlamydia in 2001 and 2002, respectively. Due to administrative changes in reporting, race/ethnicity was
missing for approximately 35% of women in 2001 and 2002, and these women were excluded from analyses. Unadjusted prevalence excluding women with
missing race/ethnicity in 2001 and 2002 (reported above) was similar to unadjusted prevalence including women with missing race/ethnicity in 2001 and
2002 (10.8% and 10.5%, respectively).
similarities in trend shape. Similar racial and regional disparities
have been observed among large population-based surveys and
public high school students.13,14,17–19 Targeted chlamydia preven-
tion efforts for these groups could be considered to address these
racial and regional disparities.
The relatively stable chlamydia prevalence trends among
women and men after 2003 and racial/ethnic and regional dispar-
ities in trends highlight the need for a comprehensive understanding
of factors that drive these trends. Future research could examine
whether stable trends among NJTP enrollees have persisted after
2012 and investigate why trends have stopped declining and what
is driving disparities in prevalence, particularly among Black
women and women residing in the South and Midwest.
Our findings differ from previously reported chlamydia
prevalence trends among NJTP enrollees with respect to trend di-
rection, duration, and validity. In previous reports, prevalence de-
clined but was estimated only over the short term.8–11 While
focusing on shorter periods may avoid bias from changing tests,
it prohibits long-term trend estimation across periods with differ-
ent tests. We examined 23-year prevalence trends to generate a
comprehensive picture of chlamydia prevalence over time, and ob-
served no substantial decline after 2003.
We also used robust methods to account for measurement
error due to changing screening tests. In previous trend estimates,
measurement error was addressed by adjusting for screening tests
in generalized linear models or restricting by test type.9,10 These
methods do not properly account for test sensitivities and specific-
ities.20 To generate more valid prevalence estimates that correctly
account for measurement error, we estimated screening tests' di-
agnostic accuracy through meta-analyses, and used EM-based
maximum-likelihood regression to incorporate sensitivities and
specificities into prevalence trend estimation. We examined sev-
eral sensitivity and specificity estimates to account for random
and systematic error that may have influenced our diagnostic ac-
curacy estimates. Sensitivity analyses showed that adjusted
prevalence trend estimates were generally unaffected by a range
of plausible screening test sensitivity and specificity values.
We also evaluated the need to account for case mix by ex-
amining race/ethnicity and region of residence of NJTP enrollees
over time. The NJTP entrance criteria for socioeconomic status,
education, and age were constant throughout the study,6 and we
did not observe meaningful variation in race/ethnicity or region
over time. We could not assess whether other characteristics of
NJTP enrollees changed over time, so although entrance criteria
were consistent, enrollees’ risk profiles, particularly their sexual
behavior, may have changed. For example, nationally, condom
use among high school students increased from 1991 through
2003 but decreased between 2003 and 2015, indicating that poten-
tial changes in sexual behaviors could be a source of residual case
mix biases.21
Multiple factors other than the screening program and
biases in surveillance data could have influenced chlamydia prev-
alence trends. These factors include changes in sexual activity, in-
creased condom use, and older age of sexual debut. Decreased
Figure 1. Adjusted and unadjusted chlamydia prevalence among
women entering the NJTP (n = 389,555) from 1990 to 2012
(red lines), and men entering the NJTP (n = 303,699) from 2003
to 2012 (blue lines). Adjusted prevalence estimates and 95% CIs
account for measurement error associated with use of increasingly
sensitive chlamydia screening tests over time (Pathfinder EIA of
swabs [1990–1997], Gen-Probe PACE 2 DNA hybridization probe
of swabs or urine [1998–2006], and BD ProbeTec ET SDA of urine
[2000–2012] or swabs [2007–2012]). Adjusted estimates were
modeled using an EM algorithm incorporated into logistic
regression. Unadjusted estimates were generated from a logistic
regression model, and do not account for changes in the
diagnostic accuracy of tests.
Figure 2. Adjusted chlamydia prevalence and 95% CIs among
Hispanic (n = 61,449), Black (n = 224,936), White (n = 91,173),
and American Indian (n = 11,997) women entering the NJTP,
1990–2012 (Panel A) andHispanic (n =44,822), black (n=155,045),
white (n = 95,994), and American Indian (n = 7,838) men
entering theNJTP, 2003–2012 (panel B). Adjusted prevalence was
modeled using an EM algorithm incorporated into logistic
regression to account for measurement error due to changes in
the diagnostic accuracy of chlamydia screening tests over the
study period.
sexual activity and increased condom use drove falling teen preg-
nancy trends,22 which declined in parallel with chlamydia in the
1990s, suggesting that multiple factors played a role in the early
decline of chlamydia. But teen pregnancy continued to drop
steadily through 2012 while chlamydia trends plateaued or rose.
Our study is the first to generate long-term chlamydia
prevalence trend estimates among NJTP enrollees while properly
accounting for biases that influence observed prevalence in senti-
nel populations. We observed an initial decline in chlamydia prev-
alence among women, followed by a period of relative stability.
We also observed stable trends among men. The trends offer indi-
rect evidence that chlamydia screening programs may have been
initially effective among women on a population level, but the on-
going impact of screening in the current social context may be in-
sufficient to further reduce prevalence. Chlamydia prevalence
among high-risk youth and young adults remains alarmingly high
and supports ongoing screening and prevention efforts.
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(panel B). Adjusted prevalence was modeled using an EM algorithm
incorporated into logistic regression to account for measurement
error due to changes in the diagnostic accuracy of chlamydia
screening tests.
